| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2124395 | European Journal of Cancer | 2009 | 7 Pages |
Abstract
In this randomised trial, adjuvant treatment using tamoxifen for 2 years reduced the incidence of contralateral breast cancer by 50% in all premenopausal women, and by 90% in women <40 years of age. The effect of tamoxifen was not significantly dependent on time.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sara Alkner, Pär-Ola Bendahl, MÃ¥rten Fernö, Bo Nordenskjöld, Lisa Rydén, on behalf of the South Swedish and South-East Swedish Breast Cancer Groups on behalf of the South Swedish and South-East Swedish Breast Cancer Groups,